On Thursday 07/18/2024 the closing price of the DaVita HealthCare Partners Inc share was $136.07 on BTT.
Compared to the opening price on Thursday 07/18/2024 on BTT of $136.21, this is a drop of 0.10%.
DaVita HealthCare Partners Inc's market capitalization is $12.09 B by 87.70 M shares outstanding.
Is DaVita HealthCare Partners stock a Buy, Sell or Hold?
DaVita HealthCare Partners stock has received a consensus rating of hold. The average rating score is and is based on 6 buy ratings, 7 hold ratings, and 1 sell ratings.What was the 52-week low for DaVita HealthCare Partners stock?
The low in the last 52 weeks of DaVita HealthCare Partners stock was 71.51. According to the current price, DaVita HealthCare Partners is 192.97% away from the 52-week low.What was the 52-week high for DaVita HealthCare Partners stock?
The high in the last 52 weeks of DaVita HealthCare Partners stock was 150.00. According to the current price, DaVita HealthCare Partners is 91.99% away from the 52-week high.What are analysts forecasts for DaVita HealthCare Partners stock?
The 14 analysts offering price forecasts for DaVita HealthCare Partners have a median target of 110.21, with a high estimate of 150.00 and a low estimate of 74.00. The median estimate represents a 125.20 difference from the last price of 137.99.DaVita HealthCare Partners Stock Snapshot
137.85
Bid
100.00
Bid Size
137.99
Ask
105.00
Ask Size
7/19/2024
Date
3:59 PM
Time
0.00
Volume
136.07
Prev. Close
0.00
Open
12.10 B
Market Cap in USD
87.70 M
Number of Shares
71.51
52 Week Low
150.00
52 Week High
137.99
0.00
Dividend in USD
0.00
Dividend Yield
14.12
P/E Ratio
98.48
Free Float in %
7.62
EPS in USD
11.89
Book Value per Share in USD
22.15
Cash Flow per Share in USD
DaVita HealthCare Partners News More News
Historical Prices for DaVita HealthCare Partners
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:
0%
0
DaVita HealthCare Partners Analyst Data
Total Analysts: 14
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price
*Price Target
Lowest: 74.00
Median: 110.21
Highest: 150.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
DaVita HealthCare Partners Analyst Opinions
- All
- Buy
- Hold
- Sell
| Date | Analyst | Rating | Price | |||
|---|---|---|---|---|---|---|
| 05/06/24 | Barclays Capital | Maintained Hold | $150 | |||
| 03/06/24 | Barclays Capital | Maintained Hold | $133 | |||
| 02/14/24 | UBS | Maintained Buy | $134 | |||
| 11/17/23 | UBS | Maintained Buy | $113 | |||
| 08/07/23 | UBS | Upgraded to Buy | $142 | |||
| 05/15/23 | Bernstein | Maintained Hold | $100 | |||
| 05/09/23 | Deutsche Bank | Maintained Hold | $113 | |||
| 05/09/23 | Bank of America Merrill Lynch | Maintained Sell | $96 | |||
| 02/23/23 | Cowen and Company, LLC | Maintained Buy | $90 | |||
| 10/31/22 | Barclays Capital | Maintained Hold | $81 | |||
| 10/31/22 | UBS | Downgraded to Hold | $74 | |||
| 08/19/22 | UBS | Upgraded to Buy | $117 | |||
| 08/04/22 | Barclays Capital | Maintained Hold | $103 | |||
| 08/02/22 | Deutsche Bank | Maintained Buy | $97 |
DaVita HealthCare Partners Estimates* in USD
| 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|
| Revenue | 12,689 | 13,196 | 13,582 | - | - |
| Dividend | - | 1.67 | 0.00 | - | - |
| Dividend Yield (in %) | - | 1.21 % | 0.00 % | - | - |
| EPS | 9.63 | 10.56 | 12.22 | 14.65 | 16.91 |
| P/E Ratio | 14.33 | 13.06 | 11.29 | 9.42 | 8.16 |
| EBIT | 1,937 | 2,040 | 2,153 | 2,209 | 2,322 |
| EBITDA | 2,652 | 2,751 | 2,845 | - | - |
| Net Profit | 840 | 865 | 920 | 1,031 | 1,109 |
| Net Profit Adjusted | 851 | 874 | 950 | - | - |
| Pre-Tax Profit | 1,293 | 1,335 | 1,611 | - | - |
| Net Profit (Adjusted) | 1,196 | 1,221 | 1,699 | - | - |
| EPS (Non-GAAP) ex. SOE | 9.63 | 10.56 | 12.22 | 14.65 | 16.91 |
| EPS (GAAP) | 9.48 | 10.19 | 11.46 | - | - |
| Gross Income | 4,031 | 4,186 | 4,265 | - | - |
| Cash Flow from Investing | - | - | - | - | - |
| Cash Flow from Operations | 1,946 | 1,966 | 2,275 | - | - |
| Cash Flow from Financing | - | - | - | - | - |
| Cash Flow per Share | 15.15 | 17.15 | 18.10 | - | - |
| Free Cash Flow | 1,226 | 1,352 | 1,642 | - | - |
| Free Cash Flow per Share | - | - | - | - | - |
| Book Value per Share | 12.77 | 12.14 | 12.17 | - | - |
| Net Debt | 9,845 | 9,967 | 10,059 | - | - |
| Research & Development Exp. | - | - | - | - | - |
| Capital Expenditure | 552 | 558 | 569 | - | - |
| Selling, General & Admin. Exp. | 1,423 | 1,469 | - | - | - |
| Shareholder’s Equity | 1,089 | 982 | 948 | - | - |
| Total Assets | - | - | - | - | - |
|
Previous Quarter ending 06/30/24 |
Current Quarter ending 09/30/24 |
Next Quarter ending 12/31/24 |
Current Year ending 12/31/24 |
Next Year ending 12/31/25 |
|
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | 6 | 6 | 6 | 7 | 7 |
| Average Estimate | 2.592 USD | 2.642 USD | 2.042 USD | 9.632 USD | 10.563 USD |
| Year Ago | 1.964 USD | 2.701 USD | 1.668 USD | 7.617 USD | - |
| Publish Date | 8/6/2024 | 11/5/2024 | 2/18/2025 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | 5 | 5 | 5 | 6 | 6 |
| Average Estimate | 3,152 USD | 3,225 USD | 3,243 USD | 12,689 USD | 13,196 USD |
| Year Ago | 3,000 USD | 3,121 USD | 3,146 USD | 12,140 USD | - |
| Publish Date | 8/6/2024 | 11/5/2024 | 2/18/2025 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Income Statements in Mio. USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Sales | 12,140.15 | 11,609.89 | 11,618.80 | 11,550.60 | 11,388.48 | 11,404.85 | 10,876.63 |
| Change of sales in % | 4.57 | -0.08 | 0.59 | 1.42 | -0.14 | 4.86 | -26.24 |
| Gross profit on sales | 3,074.99 | 2,667.74 | 2,965.77 | 2,931.56 | 2,858.84 | 2,629.30 | 2,679.72 |
| Gross profit on sales change in % | 15.27 | -10.05 | 1.17 | 2.54 | 8.73 | -1.88 | -20.67 |
| Operating income | 1,601.00 | 1,312.54 | 1,770.43 | 1,683.97 | 1,755.53 | 1,501.15 | 1,622.73 |
| Operating income change in % | 21.98 | -25.86 | 5.13 | -4.08 | 16.95 | -7.49 | -8.51 |
| Income before tax | 1,177.09 | 966.28 | 1,518.49 | 1,318.26 | 1,195.44 | 1,048.48 | 1,399.79 |
| Income before tax change in % | 21.82 | -36.37 | 15.19 | 10.27 | 14.02 | -25.10 | -5.98 |
| Income after tax | 691.54 | 546.95 | 978.45 | 783.30 | 810.98 | 159.39 | 663.62 |
| Income after tax change in % | 26.44 | -44.10 | 24.91 | -3.41 | 408.79 | -75.98 | -24.58 |
Balance Sheet in Mio. USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Total liabilities | 14,876.13 | 15,454.95 | 15,500.03 | 14,865.38 | 14,578.31 | 14,286.80 | 13,251.95 |
| Long-term liabilities per share | 137.73 | 141.97 | 134.67 | 112.70 | 97.00 | 56.47 | 55.96 |
| Equity | 2,743.35 | 2,224.80 | 2,370.98 | 2,896.78 | 3,499.62 | 5,033.04 | 5,897.43 |
| Equity change in % | 48.26 | -5.72 | -45.39 | -35.15 | -42.39 | -21.04 | 0.90 |
| Balance sheet total | 17,619.48 | 17,679.75 | 17,871.01 | 17,762.16 | 18,077.93 | 19,319.83 | 19,149.38 |
| Balance sheet total change in % | -0.34 | -1.07 | 0.61 | -1.75 | -6.43 | 0.89 | -0.79 |
Key Data in USD
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
| Sales per share | 130.28 | 121.15 | 105.68 | 94.20 | 74.04 | 66.17 | 56.84 |
| P/E ratio (year end quote, basic EPS) | 14.12 | 13.08 | 12.78 | 18.38 | 14.23 | 55.93 | 20.82 |
| P/E ratio (year end quote, diluted EPS) | 14.12 | 13.08 | 12.78 | 18.38 | 14.23 | 55.93 | 20.82 |
| P/E ratio (year end quote) | 14.12 | 13.08 | 12.78 | 18.38 | 14.23 | 55.93 | 20.82 |
| Dividend yield in % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Equity ratio in % | 5.99 | 4.03 | 4.23 | 7.79 | 11.80 | 19.17 | 24.49 |
| Debt ratio in % | 84.43 | 87.42 | 86.73 | 83.69 | 80.64 | 73.95 | 69.20 |
DaVita HealthCare Partners Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| BERG CHARLES | 05/14/2024 | 363.00 | 18,640.00 | n/a | Buy | No |
| DESOER BARBARA J | 05/14/2024 | 363.00 | 363.00 | n/a | Buy | No |
| Hollar Jason M. | 05/14/2024 | 363.00 | 3,901.00 | n/a | Buy | No |
| Schoppert Wendy Lee | 05/14/2024 | 363.00 | 1,183.00 | n/a | Buy | No |
| Moore Gregory J. | 05/14/2024 | 363.00 | 5,109.00 | n/a | Buy | No |
| Arway Pamela M | 05/14/2024 | 363.00 | 24,241.00 | n/a | Buy | No |
| YALE PHYLLIS R | 05/14/2024 | 363.00 | 15,359.00 | n/a | Buy | No |
| NEHRA JOHN M | 05/14/2024 | 363.00 | 363.00 | n/a | Buy | No |
| Schechter Adam H | 05/14/2024 | 363.00 | 2,988.00 | n/a | Buy | No |
| DESOER BARBARA J | 05/09/2024 | 5,030.00 | 10,954.00 | 138.81 | Sell | No |
| STAFFIERI MICHAEL DAVID | 03/14/2024 | 12,008.00 | 92,978.00 | 136.00 | Sell | No |
| HEARTY JAMES O | 03/14/2024 | 1,641.00 | 24,844.00 | 136.00 | Sell | No |
| HEARTY JAMES O | 03/14/2024 | 305.00 | 24,060.00 | 136.00 | Sell | No |
| HEARTY JAMES O | 03/14/2024 | 479.00 | 24,365.00 | 136.00 | Sell | No |
| Waters Kathleen Alyce | 03/14/2024 | 1,669.00 | 91,892.00 | 136.00 | Sell | No |
| Waters Kathleen Alyce | 03/14/2024 | 5,386.00 | 93,561.00 | 136.00 | Sell | No |
| Waters Kathleen Alyce | 03/14/2024 | 1,024.00 | 90,868.00 | 136.00 | Sell | No |
| ACKERMAN JOEL | 03/14/2024 | 8,064.00 | 175,510.00 | 136.00 | Sell | No |
| BERG CHARLES | 03/14/2024 | 366.00 | 18,277.00 | n/a | Buy | No |
| Arway Pamela M | 03/14/2024 | 366.00 | 23,878.00 | n/a | Buy | No |
| Moore Gregory J. | 03/14/2024 | 366.00 | 4,746.00 | n/a | Buy | No |
| NEHRA JOHN M | 03/14/2024 | 366.00 | 366.00 | n/a | Buy | No |
| Schoppert Wendy Lee | 03/14/2024 | 366.00 | 820.00 | n/a | Buy | No |
| DESOER BARBARA J | 03/14/2024 | 366.00 | 366.00 | n/a | Buy | No |
| Hollar Jason M. | 03/14/2024 | 366.00 | 3,538.00 | n/a | Buy | No |
DaVita HealthCare Partners Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2023 | DaVita HealthCare Partners Inc | 0.00 | 0.00 | USD |
| 2022 | DaVita HealthCare Partners Inc | 0.00 | 0.00 | USD |
| 2021 | DaVita HealthCare Partners Inc | 0.00 | 0.00 | USD |
| 2020 | DaVita HealthCare Partners Inc | 0.00 | 0.00 | USD |
| 2019 | DaVita HealthCare Partners Inc | 0.00 | 0.00 | USD |
| 2018 | DaVita HealthCare Partners Inc | 0.00 | 0.00 | USD |
| 2017 | DaVita HealthCare Partners Inc | 0.00 | 0.00 | USD |
| 2016 | DaVita HealthCare Partners Inc | 0.00 | 0.00 | USD |
| 2015 | DaVita HealthCare Partners Inc | 0.00 | 0.00 | USD |
| 2014 | DaVita HealthCare Partners Inc | 0.00 | 0.00 | USD |
| 2013 | DaVita HealthCare Partners Inc | 0.00 | 0.00 | USD |
| 2012 | DaVita HealthCare Partners Inc | 0.00 | 0.00 | USD |
| 2011 | DaVita HealthCare Partners Inc | 0.00 | 0.00 | USD |
| 2010 | DaVita HealthCare Partners Inc | 0.00 | 0.00 | USD |
| 2009 | DaVita HealthCare Partners Inc | 0.00 | 0.00 | USD |
*Yield of the Respective Date
DaVita HealthCare Partners Inc Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | 2.592 USD | Q2 2024 Earnings Release | 08/06/2024 |
| Earnings Report | 2.642 USD | Q3 2024 Earnings Release | 11/05/2024 |
| Earnings Report | 2.042 USD | Q4 2024 Earnings Release | 02/18/2025 |
| Earnings Report | 2.446 USD | Q1 2025 Earnings Release | 05/13/2025 |
| Earnings Report | 2.819 USD | Q2 2025 Earnings Release | 07/31/2025 |
DaVita HealthCare Partners Inc Past Events
| Event | Actual EPS | Info | Date |
|---|---|---|---|
| Annual General Meeting | - | Annual General Meeting | 06/06/2024 |
DaVita HealthCare Partners Profile
DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services, and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.
Moody’s Daily Credit Risk Score
DaVita HealthCare Partners Shareholder
| Owner | in % |
|---|---|
| Freefloat | 98.48 |
| Berkshire Hathaway, Inc. | 41.16 |
| Berkshire Hathaway, Inc. (Investment Management) | 41.16 |
| The Vanguard Group, Inc. | 7.21 |
| Vanguard Group, Inc. (Subfiler) | 6.87 |
| State Street Corp. | 2.94 |
| BlackRock Fund Advisors | 2.11 |
| Pacer Advisors, Inc. | 1.92 |
| Vanguard Total Stock Market ETF | 1.75 |
| BlackRock Institutional Trust Co. NA | 1.54 |
| Vanguard 500 Index Fund | 1.52 |
| Geode Capital Management LLC | 1.45 |
| Vanguard Small Cap Index Fund | 1.38 |
| Invesco Capital Management LLC | 1.36 |
| LSV Asset Management | 1.27 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
DaVita HealthCare Partners Management
| Name | Job |
|---|---|
| Andrew Mohraz | Associate General Counsel & Head-Investigations |
| Christopher M. Berry | Chief Accounting Officer |
| James O. Hearty | Chief Compliance Officer |
| Javier J. Rodriguez | Chief Executive Officer & Director |
| Joel Ackerman | Chief Financial Officer & Treasurer |
| Alan Cullop | Chief Information Officer |
| Madhu Narasimhan | Chief Information Officer |
| Kathleen Alyce Waters | Chief Legal & Public Affairs Officer |
| Jeffrey A. Giullian | Chief Medical Officer-Kidney Care |
| Kenneth Gardner-Smith | Chief People Officer |
| Mahesh Krishnan | Group Vice President-Growth |
| Pamela M. Arway | Independent Chairman |
| Jason M. Hollar | Independent Director |
| Wendy Lee Schoppert | Independent Director |
| Adam H. Schechter | Independent Director |
| Charles G. Berg | Independent Director |
| Dennis W. Pullin | Independent Director |
| Gregory J. Moore | Independent Director |
| Barbara Jean Desoer | Independent Non-Executive Director |
| Phyllis R. Yale | Independent Non-Executive Director |
| Nic Eliason | Investor Relations Contact |
| Samantha A. Caldwell | Secretary |
| Jeffrey Wagner | Senior Vice President |
| Bruce E. Ware | Vice President |